Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

17.31 -0.08 (-0.46%)
Streaming Delayed Price Updated: 2:04 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced. 
Via Investor's Business Daily
Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy
Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile. 
Via Benzinga
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,... 
Via Benzinga
Why Biohaven Stock Triumphed on Tuesday
Via The Motley Fool
What's Going On With Merus Stock Monday?
Merus announced a research collaboration and license agreement with Biohaven. 
Via Benzinga
BHVN Stock Earnings: Biohaven Misses EPS for Q2 2024
BHVN stock results show that Biohaven missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Biohaven Just Hurdled An FDA Setback — And Its Moving Lines
The company could soon add a new, high-value treatment to its portfolio. 
Via Investor's Business Daily
Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations, SEC Creates Crypto Task Force
The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force dedicated to the development of a clear and comprehensive regulatory... 
Via Benzinga
Topics Regulatory Compliance
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
From Merus N.V.
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval
Biohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and regulatory milestones. 
Via Benzinga
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well. 
Via Benzinga
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
Biohaven reported taldefgrobep data showing motor function gains in SMA and plans to advance obesity studies with an autoinjector in 4Q24. 
Via Benzinga
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy
The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Acuity Brands, Nike And 3 Stocks To Watch Heading Into Tuesday
 
Via Benzinga
Hewlett Packard Enterprise, Nvidia, Progress Software And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
Biohaven, a clinical-stage biopharmaceutical company, is attracting investors with promising results for its experimental drug. 
Via MarketBeat
Dow Gains Over 50 Points; Elevai Labs Shares Plummet
 
Via Benzinga
Topics Stocks
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Crude Oil Down Over 1%; US Manufacturing PMI Falls In September
 
Via Benzinga
Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise
Biohaven announced topline results from its pivotal Study BHV4157-206-RWE, showing that troriluzole significantly slowed disease progression in spinocerebellar ataxia patients over three years. The... 
Via Benzinga
Biohaven, Tesla And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease
The company is hoping to soon file for approval of what could be the first SCA treatment. 
Via Investor's Business Daily
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Biohaven Stock Earns Relative Strength Rating Upgrade
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
Via Investor's Business Daily
$1M Bet On Biohaven? Check Out These 3 Stocks Insiders Are Buying
 
Via Benzinga
The 3 Smartest Healthcare Stocks to Buy With $1K Right Now
The healthcare stocks to buy deserve more respect from investors who seek top-level growth outside of the tech sector. 
Via InvestorPlace
HP Posts Upbeat Earnings, Joins Foot Locker, American Superconductor, Red Robin Gourmet Burgers And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.